{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:42:24Z","timestamp":1786178544759,"version":"build-2736575974"},"reference-count":11,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of subcutaneous depemokimab-ulaa as add-on therapy in the treatment of severe eosinophilic asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed database, Embase, and ClinicalTrials.gov were searched using the following terms: depemokimab, depemokimab-ulaa, Exdensur, and GSK3511294.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Articles published in English between January 2020 and March 2026, related to pharmacology, safety, efficacy, and clinical trials, were reviewed. Four studies met inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      In phase 3 trials, SWIFT-1 and SWIFT-2, depemokimab-ulaa demonstrated comparable reductions in elevated blood eosinophil (EOS) counts when compared to other interleukin-5 (IL-5) targeting therapies in patients with severe eosinophilic asthma. The annualized exacerbation rates were 0.46 and 0.56 with depemokimab-ulaa vs 1.11 and 1.08 with placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), respectively. There were no differences in other outcomes that were studied. In the phase 3 NIMBLE trial, depemokimab-ulaa did not meet the noninferiority margin when patients were switched from other anti-IL-5 therapies. Depemokimab-ulaa maintained a favorable safety profile, with no serious adverse events or deaths considered to be related to the drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>When compared with other anti-IL-5 agents, depemokimab-ulaa might serve as an effective alternative option with its twice-yearly dosing offering a significant advantage potentially improving patient adherence and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Depemokimab-ulaa\u2019s twice-yearly dosing offers a convenient alternative to other anti-IL-5 therapies as add-on treatment for severe eosinophilic asthma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261472893","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T07:33:39Z","timestamp":1786001619000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2499-7250","authenticated-orcid":false,"given":"Lauren","family":"Linenfelser","sequence":"first","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-8247","authenticated-orcid":false,"given":"Melissa","family":"Lipari","sequence":"additional","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"},{"name":"Henry Ford St. John Hospital, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini","family":"Kale-Pradhan","sequence":"additional","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"},{"name":"Henry Ford St. John Hospital, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"The Global Initiative for Asthma. GINA guidelines. Published Online May 2026. Accessed July 20 2026. https:\/\/ginasthma.org\/2026-gina-strategy-report\/"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.04.013"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02125-0"},{"key":"e_1_3_2_5_2","unstructured":"Exdensur depemokimab-ulaa. Package insert. GlaxoSmithKline LLC. Accessed June 3 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761458Orig1s000lbl.pdf"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1783889"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15002"},{"key":"e_1_3_2_8_2","unstructured":"UpToDate. Depemokimab-ulaa: drug Information. Published online 2026. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7663640?cesid=7KLeIupAKYh&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Ddepemokimab-ulaa%26t%3Dname%26acs%3Dfalse%26acq%3Ddepemoki"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajrccm\/aamag031"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13885"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261472893","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261472893","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261472893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:49:57Z","timestamp":1786175397000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261472893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":11,"alternative-id":["10.1177\/10600280261472893"],"URL":"https:\/\/doi.org\/10.1177\/10600280261472893","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"10600280261472893"}}